@FierceBiotech: Baxter bets $60M on Cell Therapeutics' blood cancer drug. Article | Follow @FierceBiotech
@JohnCFierce: Vanda jumps again as FDA panel smiles on sleep-disorder drug. More | Follow @JohnCFierce
@DamianFierce: ICYMI: Sanofi gets mixed FDA blessing for MS drug Lemtrada. Story | Follow @DamianFierce
@EmilyMFierce: From FierceBiotech Research: Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg. Article | Follow @EmilyMFierce
> Sorrento Therapeutics picked up biotech Concortis BioSystems for about $12 million, absorbing the company's antibody-drug conjugate technology. News
> Despite ongoing investigations and mounting scrutiny, Big Pharma has hardly given up on China, and both Johnson & Johnson ($JNJ) and Merck KGaA are plotting expansions in the country. Article
> Diagnostics outfit CardioDx is the latest life sciences company to postpone its IPO, holding off on a planned $92 million debut. Story
@FierceMedDev: Trending on FierceMedicalDevices: Report: J&J plans layoffs, revamp to jumpstart diabetes arm. Story | Follow @FierceMedDev
@MarkHFierce: NeuroPace won the FDA's blessing for a neurostimulation implant to treat epilepsy. More | Follow @MarkHFierce
@MichaelGFierce: Next-gen sequencing tech from GenapSys nets $37M round. Item | Follow @MichaelGFierce
> In a blow to Edwards, German court restores Medtronic's right to sell heart valve. Article
> As other IPOs move forward, CardioDx pulls back. More
> Kimberly-Clark seeks to spin off healthcare, medical devices arm. News
Pharma News
@FiercePharma: So, if you're not among the 103K people who have already, check it out. Report | Follow @FiercePharma
@EricPFierce: With a market as big as China, you can't let a bribery case scare you away. J&J, Merck to build new plants. More | Follow @EricPFierce
@CarlyHFierce: Tufts University report: 71% of revenue from the top 10 best-selling meds last year came from biotech products. More | Follow @CarlyHFierce
> GSK expanding further in India with £85M facility, CEO Witty says. News
> Drugmakers confront new pay-to-delay cases under new rules. Report